Soon no more reimbursement for rapid diagnostic orientation tests (Trod) Covid-19 carried out in pharmacies? This is what the Ministry of Health announced this Tuesday to the pharmacists’ unions. At issue: the desire of the ministry to publish an order ending the measures linked to the state of emergency, taken in the context of the Covid-19 crisis.
“It is a real surprise for us today, especially since the Prime Minister, as part of his general policy speech, and Madame Vautrin both clearly said that there would be no dereimbursement. We cannot say everything and its opposite”protests Pierre-Olivier Variot, president of the USPO.
“Nonsense for public health”
In a press release, the union also denounced “the removal of almost all epidemic curbing measures, and in particular the delisting of masks, particularly for the immunocompromised, and antigenic tests”, considering this decision as “a non- meaning for public health. Especially since the announcement comes in the midst of an epidemic crisis, with numerous white plans triggered in hospitals across the country.
“Without reimbursement for tests, it will no longer be possible to monitor the evolution of epidemics. We also risk returning to an automatic prescription of antibiotics. This is not going in the right direction,” deplores Pierre-Olivier Variot.
Towards inclusion in common law for vulnerable people?
“It is logical that we put an end to the measures taken within the framework of the state of emergencyreacts Philippe Besset, president of the Federation of Pharmaceutical Unions of France (FSPF). However, I am campaigning for the reimbursement of Trod influenza, covid-19 and RSV for people in the target population (over 65 years old and with comorbidities) to be included in common law. He specifies that the High Authority for Health (HAS) should set up a working group on the subject, to assess the relevance of reimbursement.
The USPO also denounces an “unjustifiable delay” by the HAS in evaluating the reimbursement of combined Covid/flu and Covid/flu/RSV Trods. “The study on reimbursement, announced in 2022, has still not been carried out, limiting the effectiveness of the health response to virulent epidemics,” specifies the union in its press release.
The decree, for its part, could be issued by the council of the National Health Insurance Fund (Cnam) within a maximum of two weeks. There will therefore in all cases be a latency period between the end of systematic reimbursement and possible reimbursement for the target population, if it is deemed relevant by the HAS.
Related News :